GLP-1 Supply-Demand Forecast 2026-2030: When Does Supply Catch Up With Demand?

Three years ago a patient seeking semaglutide had a one in three chance of finding their dose in stock. Today the branded supply has largely caught up. But "caught up" understates what's happening — the entire industry is racing against a demand wave that, when fully unlocked, is at least 5-10x current prescription volume. This is the article we wrote so patients, journalists, and policy people can stop guessing about whether the medication will be available, and start planning around what we actually know.

We update this forecast weekly; the JSON file below carries the actual last-modified date rather than this prose, since a hardcoded date in an article goes stale between edits. The full structured forecast data is available as a machine-readable JSON file — researchers and journalists are welcome to cite or ingest it.

Where we are today (May 2026)

Branded GLP-1 supply has stabilised in the major markets. The FDA removed tirzepatide from its drug shortage list in October 2024 and semaglutide in February 2025. The MHRA, EMA, and other regulators have followed. In day-to-day terms, a US patient with a Wegovy prescription and insurance authorisation can now fill it; a UK patient with a private prescription for Mounjaro can typically obtain it within days; an Indian patient can choose from 40+ CDSCO-approved generic semaglutide brands (50+ brand names) at roughly 10% of the branded import price.

What this means: the Phase 1 supply crisis (2023-2025) is over for branded medication in supplied markets. It does not mean the market is in equilibrium. Demand at current prices is the demand-at-current-prices number. Demand at $40/month — the Indian generic price — is a different and much larger number. We are early in a multi-year process of supply expansion, generic spread, and demand unlock.

The 2023-2025 shortage in context

The first GLP-1 shortage was in many ways predictable and in some ways not. The predictable part: a single-ingredient injectable medication that became a cultural phenomenon was always going to outrun manufacturing capacity. The unpredictable part: the bottleneck was not the active ingredient.

Both Novo Nordisk and Eli Lilly have substantial active pharmaceutical ingredient (API) capacity. Solid-phase peptide synthesis at industrial scale is mature chemistry. The shortage was driven by fill-finish capacity — the sterile manufacturing step where the bulk peptide is filled into vials or, more critically, into the pre-filled disposable injection pens that patients use. Pen and auto-injector manufacturing requires specialised aseptic lines that take 18-36 months to commission and are similar to the production lines that have served the insulin market for decades.

The shortage taught the industry three things. First, fill-finish is the binding constraint, and the industry-wide pen-line capacity built for diabetes is not enough for a market that includes obesity. Second, demand at any reasonable price elasticity is essentially unbounded — there is no "satiation point" at which addressable demand stops growing. Third, the supply chain is geographically concentrated in a small number of facilities, which makes it vulnerable to a single quality event or regulatory action.

Novo Nordisk's manufacturing response

Novo Nordisk has committed in excess of $20 billion to GLP-1 manufacturing capacity expansion over 2023-2027. The most consequential moves:

Catalent acquisition: In February 2024, Novo Holdings acquired Catalent Inc. for approximately $16.5 billion. Three of the acquired fill-finish sites — in Anagni (Italy), Brussels (Belgium), and Bloomington (Indiana) — were transferred to Novo Nordisk to dedicate to semaglutide. This was the single largest fill-finish capacity addition ever made for a single molecule by a single company.

Kalundborg, Denmark: Continued multi-billion-dollar expansion of the company's home API and fill-finish complex, with new lines coming online progressively through 2025-2027.

Clayton, North Carolina: Multi-billion-dollar expansion of the existing Clayton facility to add fill-finish capacity.

Process intensification: Investments in continuous manufacturing and higher-throughput aseptic lines that yield more doses per unit of facility footprint.

Athlone, Ireland (Monksland site): In March 2026 Novo announced an additional €432 million ($506 million) investment at the Athlone facility, dedicated specifically to oral GLP-1 tableting capacity for the Wegovy pill and other oral semaglutide products. Construction runs through end 2027-2028, adding up to 500 construction jobs.

The combined effect is that Novo Nordisk's branded semaglutide capacity in 2026 is materially higher than it was in 2023, and the trajectory through 2027 sees further step-changes as the Catalent sites complete their transition and the Athlone oral facility comes online.

Eli Lilly's manufacturing response

Eli Lilly is making the equivalent investment for tirzepatide:

Lebanon, Indiana: Two manufacturing campuses announced — the first in April 2022 ($2.1 billion), a second in May 2024 ($5.3 billion). Combined investment exceeds $9 billion. These are API and fill-finish.

Concord, North Carolina ($1 billion+) and Research Triangle Park, North Carolina (multi-billion): Additional API and fill-finish capacity.

Limerick, Ireland: Expansion of the existing Limerick site for biotech and parenteral manufacturing.

Indianapolis: Expansion of the company's home parenteral manufacturing.

Huntsville, Alabama (API facility): $6 billion facility announced December 9, 2025. Construction begins 2026 with completion in 2032. Will manufacture active pharmaceutical ingredients for orforglipron (Foundayo) and other drugs. Creates 3,000 construction jobs and 450+ permanent skilled roles.

Katwijk, Netherlands (oral medicines facility): $3 billion facility announced November 3, 2025 at Leiden Bio Science Park. Construction 2026 (pending local approvals); production start 2030. Dedicated to oral medicines including orforglipron and other oral products for European patients. Creates 500 jobs and 1,500 construction roles.

By 2027 Lilly's tirzepatide manufacturing capacity is forecast to support the company's "many millions of patients globally" stated ambition. Total committed US manufacturing investment now exceeds $27 billion; the global total including Netherlands and other international sites is higher.

The generic capacity question

While Novo and Lilly build branded capacity, an entirely separate manufacturing base is coming online for generic semaglutide outside the OECD patent zone:

India: Following the March 20, 2026 patent expiry, the first CDSCO-approved generic was on pharmacy shelves within 48 hours (Natco, first to market); within three weeks, press tracking counted roughly 15 manufacturers and licensing partners on the market, at prices up to 90% below branded. By May 2026, press tracking counted 40+ CDSCO-approved generic semaglutide manufacturers and over 50 brand names in the Indian market, including Dr Reddy's (Obeda), Natco (Semanat), Sun Pharma (Sematrinity), Glenmark (GLIPIQ), Zydus (Semaglyn), Eris (Sundae), Alkem, Mankind, Torrent, USV, Wockhardt, Biocon, Aurobindo, and others — Lupin co-markets Zydus's licensed product rather than manufacturing independently, and Cipla's launch was not confirmed within the first three weeks. Indian peptide manufacturing capacity is large and scalable. Our own conservative estimate — a Magistra projection derived from announced manufacturer and brand counts, not an independently sourced figure — puts combined Indian generic capacity at 10-30 million patient-years annually within 18-24 months of launch — far in excess of current Indian domestic demand, with significant export capability to other patent-expired markets.

China: Domestic semaglutide applications are in the NMPA review queue from manufacturers including Hangzhou Jiuyuan (Jikeqin, accepted for review 25 February 2026) and Huadong Medicine. As of 18 August 2026 we have found no evidence that any domestic generic has been approved and brought to market. China is in the unusual position of being both a large potential domestic market and a peptide manufacturing powerhouse.

Brazil: ANVISA-approved semaglutide analogues now from 6+ manufacturers. Brazilian capacity primarily serves the domestic market. Note: Brazil classifies semaglutide as a biological product; competing products are registered with ANVISA as new drugs (synthetic analogues), not traditional generics. The first synthetic semaglutide pen, Ozivy (EMS SA), was registered by ANVISA on 26 May 2026 and went on sale from 15 June 2026 at a launch price of R$452/month (~US$79) — T2D indication. EMS's São Paulo plant has capacity of up to 40 million pens per year. On July 29, 2026, ANVISA approved five additional semaglutide products in a single day — including Owozy (Sandoz/Adalvo) and Seemasun (Sun Pharma/Hypera) — bringing the total to 6+ ANVISA-approved synthetic semaglutide products. All approved products await CMED (Brazil's price authority) price ceiling authorization before pharmacy sale can begin.

Canada: Three generics now approved. Dr. Reddy's received Health Canada approval April 29, 2026 (T2D); Apotex received approval May 1, 2026 (T2D, first Canadian-based company) and commercially launched Apo-Semaglutide Injection on May 14, 2026; Apotex received a third approval on June 29, 2026 for Sevmia (semaglutide injection) for chronic weight management in patients 12 and older — the first generic semaglutide for weight management approved in Canada, and in any G7 country. Health Canada is reviewing 6 additional generic semaglutide submissions. Mexico: In regulatory review at COFEPRIS; launch expected 2026-2027.

This generic capacity is not currently legally exportable to the United States, EU, UK, Japan, or Australia, where the composition patent runs to approximately 2031. It is, however, exportable between patent-expired jurisdictions — so Indian generic capacity can serve Brazilian, Canadian (after launch), South African, and other markets where patents have lapsed.

The demand picture is shifting structurally

The supply story is dramatic, but the demand story is the larger force. GLP-1 demand was growing from a weight-loss starting point. It is now expanding into multiple co-morbidity indications, each of which can substantially expand the addressable patient population:

Cardiovascular outcomes: The SELECT trial (Lincoff et al., NEJM November 2023) showed semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in non-diabetic patients with established cardiovascular disease and overweight/obesity. The FDA approved a cardiovascular indication for Wegovy in March 2024. This unlocked broader insurance coverage in the US — many commercial plans that previously excluded weight-loss now cover Wegovy on cardiovascular grounds.

Cardiovascular outcomes — tirzepatide (Mounjaro): The SURPASS-CVOT trial (13,299 participants, 640 sites, 30 countries, median 4-year follow-up), head-to-head against Trulicity (dulaglutide 1.5mg), showed tirzepatide non-inferior for MACE reduction in adults with T2D at high cardiovascular risk: HR 0.92 (95.3% CI: 0.83–1.01), 8% lower MACE-3 rate. The FDA approved Mounjaro for cardiovascular risk reduction on August 28, 2026 — the first dual GIP/GLP-1 receptor agonist to carry a cardiovascular indication. This expands Mounjaro reimbursement to T2D patients with established cardiovascular disease.

Chronic kidney disease: The FLOW trial (Perkovic et al., NEJM 2024) showed semaglutide reduced kidney disease progression and cardiovascular death in T2D patients with CKD. This expands the diabetes-with-CKD patient pool and provides another reimbursement vector.

Obstructive sleep apnea: The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024) showed tirzepatide significantly reduced sleep apnea severity. The FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in December 2024. Sleep apnea is reimbursed by most insurance.

Heart failure with preserved ejection fraction (HFpEF): The STEP-HFpEF trial showed semaglutide improved heart failure symptoms and exercise capacity in obese HFpEF patients. Label expansion likely.

Alcohol use disorder: Multiple Phase 2 readouts suggest GLP-1 medications may reduce alcohol consumption. Larger trials are underway.

Alzheimer's disease (EVOKE/EVOKE+ — NEGATIVE): The Phase 3 EVOKE and EVOKE+ trials of oral semaglutide in 3,808 early-stage Alzheimer's patients found no significant slowing of disease progression versus placebo at 2 years, despite improvements in AD-related biomarkers and ~30% reduction in peripheral inflammation markers. Published in The Lancet, March 19, 2026. This indication is closed for semaglutide. Residual interest in GLP-1 mechanism for neuroinflammation at earlier disease stages remains hypothesis-generating only.

Liver disease (MASH): Semaglutide (Wegovy 2.4mg) FDA approved August 2025 for non-cirrhotic MASH with F2-F3 fibrosis — ESSENCE Phase 3: 62.9% vs 34.3% placebo achieved steatohepatitis resolution; 36.8% vs 22.4% fibrosis improvement. Tirzepatide (Zepbound) FDA approved early 2026 on breakthrough therapy designation — SYNERGY-NASH Phase 2: 73.3% MASH resolution at 52 weeks. Both now in EASO 2026 guidelines. Adds meaningful patient pool and new insurance reimbursement vectors.

Every successful trial adds patients to the addressable pool and adds reimbursement vectors that expand access.

The oral GLP-1 wave (two products now on the US market)

Before the April 2026 Foundayo launch, another oral GLP-1 had already entered the US market. Novo Nordisk's Wegovy pill (oral semaglutide 25mg) was FDA approved on December 22, 2025 — making it the first oral GLP-1 approved specifically for weight management in the United States — and launched broadly in US pharmacies from January 5, 2026. The OASIS 4 trial showed 16.6% mean weight loss. Self-pay pricing: $149/month for the 1.5mg starting dose; $199/month for the 4mg dose (effective September 1, 2026); $299/month for maintenance doses (9mg and 25mg); commercial insurance copay as low as $25/month with Novo's savings card. Novo's Q1 2026 results (reported May 6, 2026) showed oral Wegovy generated 2.26 billion DKK ($355 million) in its first quarter — 1.3 million prescriptions and the strongest-ever GLP-1 US volume launch. By early June 2026, Novo announced that oral Wegovy had surpassed 3 million total prescriptions — approximately one prescription filled every five seconds — with over 80% of new prescriptions going to patients not previously on any GLP-1 therapy (Novo ADA announcement, June 7, 2026). By Q2 2026 close, oral Wegovy had surpassed 5 million total cumulative US prescriptions (~267,000 new prescriptions per week as of July 17, 2026; UK launch reached approximately 300,000 patients in its first three weeks) per Novo Q2 2026 earnings August 4, 2026. To support oral production, Novo announced a €432 million ($506 million) investment in its Athlone, Ireland facility (March 2026) dedicated to oral GLP-1 tableting capacity, with construction through end 2027-2028.

On May 22, 2026, the EMA's CHMP adopted a positive opinion recommending EU marketing authorisation of the Wegovy pill (oral semaglutide 25mg) — the first oral GLP-1 recommended for EU weight management. CHMP also recommended approval of the Wegovy 7.2mg single-dose pen (STEP UP trial: 20.7% mean weight loss in adults with obesity; STEP UP T2D: 14.1%). On July 15, 2026, the European Commission granted formal marketing authorisation for both the Wegovy pill (oral semaglutide 25mg) and the Wegovy 7.2mg single-dose pen across all EU member states — the fifth global regulatory approval of the Wegovy pill, following the US, UK, UAE, and Bahrain.

Ahead of the EU formal decision, the MHRA approved the Wegovy pill (oral semaglutide 25mg) for weight management in the United Kingdom on 11 June 2026 — making the UK the first European country to grant marketing authorisation for an oral GLP-1 tablet for weight loss. The approved indication covers adults with initial BMI ≥30 kg/m², or ≥27 kg/m² with a weight-related comorbidity. The OASIS trial, which supported the MHRA submission, demonstrated 13.6% mean weight loss at 64 weeks versus 2.4% for placebo. Approved dosing steps: 1.5mg → 4mg → 9mg → 25mg. Private launch in UK expected from £99/month (starting doses) to £199-269/month (maintenance doses); NHS availability requires a separate NICE appraisal, which has not yet been initiated.

On 10 August 2026, the MHRA approved Foundayo (orforglipron) in the UK — making the UK the first country in Europe to authorise orforglipron. The approved indications cover both weight management (adults with BMI ≥30, or ≥27 with a weight-related comorbidity) and type 2 diabetes. Foundayo is a once-daily oral small-molecule GLP-1 agonist with no food or water restrictions (unlike oral semaglutide). Clinical data showed 11.2% mean weight loss at the highest dose over 72 weeks. Private launch in the UK is expected from approximately £129/month (indicative; Lilly UK list pricing not officially confirmed at time of writing); NHS availability requires NICE appraisal, not yet initiated — earliest expected late 2027.

Eli Lilly's orforglipron (Foundayo) — a small-molecule oral GLP-1 agonist, chemically distinct from peptide GLP-1s like semaglutide and tirzepatide — was FDA approved on April 1, 2026 for weight management in adults with obesity or overweight with a weight-related condition, and also for type 2 diabetes and cardiovascular risk. The supply-side implications this article previously forecast as conditional are now confirmed:

Manufacturing: Small-molecule oral medication is dramatically cheaper to manufacture than peptide injectables. The fill-finish bottleneck disappears entirely.

Distribution: Tablets do not require cold chain. They can be shipped through normal pharmacy supply chains globally.

Capacity expansion: Small-molecule capacity can be added much faster than peptide aseptic capacity.

Patient access: No injection barrier, no cold-chain barrier, much simpler prescription fulfilment.

Foundayo launched at self-pay pricing of $149/month (lowest dose) to $299/month (maintenance doses 5.5-17.2 mg) via LillyDirect, significantly below Wegovy's $1,349/month list. Commercial insurance copays as low as $25/month with Lilly's savings card. Medicare Part D eligibility expected from July 1, 2026 at approximately $50/month for covered T2D/cardiovascular indications. This is the most material cost-reduction event for US patients since the 2023-2025 shortage resolved — a legal, oral, branded GLP-1 option at a fraction of injectable branded prices.

New molecules in late-stage development

Beyond the marketed semaglutide, tirzepatide, and liraglutide, several next-generation molecules are in late-stage development:

Retatrutide (Eli Lilly): Triple agonist (GIP/GLP-1/glucagon). Phase 3 (TRIUMPH programme, multiple trials reading out 2026). TRIUMPH-1 (pivotal registrational obesity trial, topline May 21, 2026; full data presented at ADA 86th Scientific Sessions, June 2026): 28.3% mean body weight loss at 80 weeks on 12mg (vs 2.2% placebo) in 2,339 non-diabetic adults with obesity or overweight and at least one comorbidity; 30.3% at 104 weeks in the BMI≥35 subgroup (85 lbs average); 45.3% of 12mg participants achieved ≥30% body weight loss — a threshold long associated with bariatric surgery outcomes. All doses met primary and key secondary endpoints. ADA 2026 sleep apnea basket (nested within TRIUMPH-1): retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60% (~36 fewer breathing events per hour) — comparable in magnitude to tirzepatide's approved SURMOUNT-OSA result. TRIUMPH-4 (obesity + knee osteoarthritis): 28.7% at 68 weeks, 75.8% reduction in knee pain scores; new safety signal: dysesthesia in 20.9% at 12mg vs 0.7% placebo, characterised as generally mild and rarely leading to discontinuation. On July 23, 2026, Lilly announced that TRIUMPH-2 and TRIUMPH-3 (adults with obesity and established cardiovascular disease) both met their primary endpoints — TRIUMPH-3 showed 22.6% mean weight loss at 80 weeks (55.8 lbs average on the highest dose). Lilly confirmed NDA submission in Q1 2027 (revised from Q4 2026 estimate); FDA approval expected late 2027-2028. A regulatory classification dispute is also pending: FDA ruled retatrutide is not a biologic and must be filed as an NDA (5-year exclusivity) rather than a BLA (12-year exclusivity); a federal court vacated FDA's decision in August 2026 and remanded for reconsideration; Lilly continues to plan a BLA filing in Q1 2027 — the outcome is economically material, as BLA classification would significantly extend the pre-biosimilar window (sources: biospace.com August 7, 2026; zamann-pharma.com August 7, 2026).

Survodutide (Boehringer Ingelheim / Zealand Pharma): Dual GLP-1/glucagon agonist. Phase 3 complete (SYNCHRONIZE programme, data at ADA 86th Scientific Sessions, June 2026). SYNCHRONIZE-1 (725 adults with obesity; 76 weeks; published NEJM at ADA 2026): 16.6% mean body weight loss versus placebo; visceral fat -34%, liver fat -63%, lean mass loss ≤10.8% of total tissue change — strong lean-mass-preservation profile. SYNCHRONIZE-MASLD (metabolic-associated steatotic liver disease cohort; published Nature Medicine at ADA 2026): 60% of participants achieved liver fat normalisation (primary endpoint met). No regulatory submission timeline announced.

Cagrisema (Novo Nordisk): Combination of cagrilintide and semaglutide. NDA submitted December 2025. REDEFINE 1 showed 20.4% weight loss. The REDEFINE 4 head-to-head trial (reported February 23, 2026) failed to demonstrate non-inferiority to tirzepatide — Novo confirmed the result at its Q1 2026 earnings call. Commercial viability is now questioned given the tirzepatide comparator result.

MariTide (Amgen): Phase 3.

CT-388 (Roche, formerly Carmot): Dual GLP-1/GIP agonist. Phase 2 readouts strong.

Pfizer's danuglipron programme was discontinued in 2025 after liver enzyme elevations and other safety signals — a useful reminder that not every late-stage candidate reaches market.

The 2026-2030 supply-demand projection

The forecast we maintain has the following directional shape:

These ranges are wide on purpose — addressable demand depends heavily on what fraction of the global obesity and obesity-related comorbidity population gets prescribed and reimbursed. The structural pattern is:

Branded supply growth is roughly linear and forecastable (capex is mostly committed).

Generic supply growth in patent-expired markets is faster than linear (low capex per added unit, multiple competitive entrants).

Demand growth is non-linear and depends on policy switches — particularly US Medicare coverage of anti-obesity medication, which Magistra estimates (not independently sourced; see the policy section below for the basis) could add on the order of 50-100 million eligible patients in the US alone.

Three scenarios for when supply meets unlocked demand:

Bull case (supply abundant by 2028): Combined branded + Indian generic capacity ramps faster than expected; orforglipron approves; OECD demand stays gated by insurance. In this scenario branded prices begin to soften before 2031 patent expiry.

Base case (supply meets demand around 2030-2032): Branded capacity continues steady growth; generic Indian capacity scales but remains regional; orforglipron approves and modestly expands access; 2031 OECD generic wave is the inflection.

Bear case (chronic constraint through mid-2030s): US Medicare coverage unlocks; major emerging-market reimbursement (China, Brazil) expands; demand unlock outpaces supply; chronic shortages return in the late 2020s.

Magistra's central case is closer to the base case, with non-trivial probability on the bull case. We do not currently see the bear case as the most likely path, but it would only require one or two demand-unlock policy events to become so.

The 2031 OECD generic wave

The single most important date on the GLP-1 supply-demand calendar is approximately 2031, when the semaglutide composition patent lapses in the United States, EU, UK, Japan, and Australia. Generic supply ramping to serve the largest pharmaceutical markets in the world will reset prices in those markets to roughly 10-20% of branded — the same compression already visible in India.

The 2031 wave will:

Crash branded prices: Novo Nordisk and Eli Lilly have already factored this into their long-range planning. Analyst forecasts assume material price pressure on Wegovy and Ozempic from 2031.

Unlock insurance reimbursement: Insurers that exclude branded weight-loss medication today will reconsider when generic prices make the cost-benefit dramatically different.

Compress the addressable demand curve into actual demand: Many patients who want the medication today but cannot afford it will be able to fill prescriptions.

Pressure Eli Lilly's tirzepatide pricing: Tirzepatide patents extend approximately 5 years beyond semaglutide. Lilly's premium pricing for tirzepatide will be tested as patients have a generic semaglutide alternative at a fraction of the cost. Two pairs of Paragraph IV ANDA challenges have already been filed since the NCE-1 date of May 13, 2026 — Sandoz (accepted June 29, 2026) and Amneal/Adalvo (accepted July 8, 2026) — though final approval cannot come before ~2036 absent successful litigation.

This is the single largest economic event in the GLP-1 medication ecosystem for the rest of the decade.

What this means for patients

A patient making a treatment decision in 2026 should plan around the following:

Branded supply is no longer a constraint in the US, UK, EU and most major markets. If you have a prescription and can afford the medication (insurance or out-of-pocket), it is available.

Affordability is now the binding constraint, not supply. The 2023-2025 question was "can I get any?". The 2026-2030 question is "can I afford to keep taking it?".

If you are in India, Brazil, or another patent-expired market: generic semaglutide at roughly 10% of branded price is your near-certainty path. Use it.

If you are in the US, UK, or EU and considering long-term therapy: the cost picture improves materially in 2031. If you are stable on your current dose and reimbursed, plan around the lifelong-usage assumption (see our GLP-1 Economics page for 10-year cost scenarios).

Orforglipron (Foundayo) is approved as of April 2026: at $149-299/month self-pay, it is the most affordable branded GLP-1 in the US market today. For patients who prefer oral over injectable, this is available now — no waiting for 2031.

The supply scenario most worth planning around is base case, not bear case: chronic shortages are unlikely to return through the late 2020s, but a major demand-unlock event (US Medicare coverage being the most consequential) would change that.

What this means for policymakers

The GLP-1 supply-demand picture is a near-textbook case of a medication where access is gated by patent geography rather than physical scarcity. The policy levers that would change the access picture most:

US Medicare coverage of anti-obesity medication: Starting July 1, 2026, a temporary Medicare GLP-1 Bridge Program (through December 31, 2027) gives Part D beneficiaries with BMI ≥35 (or ≥27 + comorbidity) access to Wegovy, Zepbound (KwikPen), and Foundayo for obesity at $50/month copay — negotiated by CMS with Novo Nordisk and Eli Lilly under Innovation Center authority. This is a significant but temporary partial unlock: it does not change the underlying statutory prohibition (Section 1860D-2(e)(2)(A)) and expires unless further extended. Full statutory coverage via the Treat and Reduce Obesity Act (TROA, re-introduced in every Congress since 2013; current version H.R.4231/S.1973) remains the largest potential demand unlock globally. Magistra estimate, not independently sourced: on the order of 50-100 million eligible US patients on a permanent basis.

Compulsory licensing in middle-income countries: Brazil and India have used this mechanism for other medicines. It is legally available for GLP-1 outside the patent zone but politically rarely invoked.

Patent term extensions and evergreening: Novo Nordisk and Eli Lilly have a clear interest in extending patent protection through formulation and combination patents. Watching the formal patent challenges in major markets is part of any serious supply forecast.

Speeding generic regulatory pathways: jurisdictions that streamline ANDA-equivalent processes for biosimilars and complex generics will see faster supply arrival post-2031.

WHO Essential Medicines List (September 2025) + WHO obesity guideline (December 2025): In September 2025, WHO added GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide, dulaglutide — to the WHO Model Essential Medicines List for management of type 2 diabetes in high-risk groups: the first time GLP-1 RAs appeared on the EML. On December 1, 2025, WHO issued a separate global guideline with conditional recommendations for GLP-1 use in adults with obesity as part of comprehensive care. EML inclusion signals to middle-income governments and procurement agencies that national supply should be secured, increases pressure for compulsory licensing and negotiated access, and creates a framework for donor-funded programmes (Global Fund-style mechanisms). It does not automatically lower prices or mandate reimbursement, but it is the first multilateral signal that GLP-1 therapy is essential rather than elective — and the signal tends to precede access shifts by 3-5 years.

Methodology and data sources

This forecast synthesises:

Manufacturer earnings calls and investor day presentations (Novo Nordisk Q4 2024 and FY2025; Eli Lilly Q4 2024 and FY2025; investor day materials)

Capacity expansion announcements (Catalent acquisition press materials; Lebanon IN announcements; Kalundborg expansion details)

Regulatory filings (FDA shortage list, EMA notices, MHRA bulletins, CDSCO India approvals)

Public clinical trial readouts (SELECT, FLOW, SURMOUNT-OSA, EVOKE and others, all referenced via the New England Journal of Medicine, JAMA, or trial registry)

Sell-side analyst market-sizing estimates for the GLP-1 category. These diverge more than a single range implies: several banks cluster around $130-200 billion for 2030, but at least one major bank publicly revised its estimate down to under $100 billion in 2025, citing patient discontinuation rates and pricing pressure as reasons the market could undershoot the bull case. We report the spread, not a single consensus figure, because there isn't one.

Indian generic capacity tracking from manufacturer announcements and regulatory filings (CDSCO approvals, company press releases)

We update this forecast weekly. Material revisions trigger a dated change-log entry in the structured JSON dataset at `/data/glp1-supply-demand-forecast.json`. Researchers, journalists, and policy analysts are welcome to cite this work; please use the citation format on our GLP-1 Economics page.

---

Magistra Health publishes evidence-based information for patients, physicians, and decision-makers in the GLP-1 ecosystem. This article is part of our GLP-1 Economics hub, which is designed to be the most comprehensive single source on GLP-1 medication economics on the internet. Updated weekly.

Magistra is not a financial advisor and does not make investment recommendations. The forecast presented here reflects our best reading of public information as of the publication date. Actual outcomes will differ. Magistra does not provide medical advice. If you are considering a GLP-1 medication, please consult a licensed healthcare provider.